Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Sponsor
First Affiliated Hospital of Harbin Medical University
Study ID
NCT03587129
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    An anti-tumor Targeted drug

Study Details

For patients with "Platinum-resistant recurrent ovarian cancer" after second-line chemotherapy failure Using apatinib as a single drug Clinical efficacy observation Single study no control

Key Dates

Start date
Jul 10, 2018
Status verified
Jul 2018
Primary completion
Jun 14, 2020
Completion
Jun 14, 2020

Study Design

Enrollment
1 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib
    1 times a day, atapinib, 500 mg, is taken orally

Primary Outcome Measure

Objective remission rate, ORR [ Time Frame: 3 years ]

Related Studies